This Information Disclosure Statement is being electronically filed on 05 June 2007

Attorney Docket No. PB60811

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andronis, et al 29 May 2007

Serial No.: 10/593,653 Group Art Unit No.: 1713

Filed: 09/21/2006 Examiner: Not Assigned

For: SPRAY DRIED PHARMACEUTICAL COMPOSITIONS

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

## FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Nora Stein Fernandez Attorney for Applicants Registration No. 36,689

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539

King of Prussia, PA 19406-0939 Phone (610) 270-5023

Facsimile (610) 270-5090

N:\NSF\PATAPPS\PB60811\June 2007 Filing\0\_IDS\_Letter.doc

12/07/2008 /M M / / Manu Manohar/